



LANXESS – Q4 2018 proves resilience

A successful year: promise and delivery

Matthias Zachert, CEO Michael Pontzen, CFO

Safe harbor statement



The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.

This presentation contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.

2

Agenda



- 1 Executive summary FY 2018 and Q4 2018
- 2 Business and financial details Q4 2018
- 3 Back-up

FY 2018: Strategic milestones achieved



Strategic highlights	7	MAAN
Successful divestment of rubber JV (ARLANXEO)	\bigcirc	$/// \parallel$
Acquisition of Solvay's U.S. phosphorus additives business	\bigcirc	
Cooperation with Standard Lithium in El Dorado (USA)		
~€150 m brownfield and debottlenecking investments		/ _
Optimization of production network (Zárate, Ankerweg, Reynosa)		
Chemtura integration fully on track, delivering on promised synergies		

4

FY 2018: Delivered as promised - strong earnings despite FX and macro economic burden



Financial highlights

Despite weakening economy, delivery on upper end of guidance (EBITDA pre €1,016 m)

Price pass-through and volume momentum even in Q4

Stronger portfolio clearly shows resilience and enables the offsetting of weak Saltigo, Leather and Inorganic Pigments businesses


Strengthened balance sheet as platform for further growth



5


FY 2018: Improved results in three segments drive performance in tougher environment





Shareholders benefit from rising dividend and share buy-back





Dividend policy

LANXESS aims for a rising or at least stable dividend



Q4 2018: Proof of more resilient portfolio



Business highlights / lowlights

- 8% sales growth driven by volume and price increases
- ♣ EBITDA pre flat despite higher energy and freight costs
- + First indication of recovery in BU Saltigo
- Softening in automotive and construction markets
- BU Leather with potential to improve



^{*} To be proposed to the Annual General Meeting on May 23, 2019

Q4 2018: Solid financials



[€ m]	Q4 2017	Q4 2018	yoy in %
Sales	1,635	1,766	8%
EBITDA pre	179	179	0%
margin	10.9%	10.1%	
EPS (group)	-0.54	1.08	>100%
EPS pre (continuing) ¹	0.43	0.61	42%
Capex	194	240	24%

[€ m]	31.12.2017 ²	30.09.2018	31.12.2018	Δ seq%
Net financial debt ³	2,252	2,514	1,381	-45%
Net working capital	1,948	1,535	1,455	-5%

- Higher sales driven by strong pricing <u>and</u> volume increases
- Flat EBITDA pre due to price passthrough of increased raw material prices; higher volumes offset by rise in energy and freight costs
- Margin dilution reflects price passthrough
- EPS boosted by book gain from ARLANXEO divestment, reduced exceptionals and in 2017 negative U.S. tax effect
- Higher capex resulting from investments in debottleneckings
- Reduced net debt due to proceeds from ARLANXEO divestment

Q4 2018: Both segments with improved results and margins





- Price increase mainly driven by successful raw material price pass-through in BU AII
- Solid volume growth in BU AII; new contracts in BU SGO, over emphasized volumes by IFRS 15 effect
- Improved EBITDA pre and margin despite higher energy and freight cost in BU AII; BU SGO with improved utilization

[€ m]	Q4'17	Q4'18
Sales	470	562
EBITDA pre	60	73
Margin	12.8%	13.0%

Specialty Add	ditives		
Price	Volume	FX	Portfolio
+3%	-2%	+0%	+4%
		Total	+4%

- All businesses with positive price development driven by successful raw material price pass-through
- Volume decline in BU RCH due to lower auto demand
- Portfolio reflects acquisition of Solvay's U.S. phosphorus additives business
- EBITDA pre and margin also improved due to synergies

[€ m]	Q4'17	Q4'18
Sales	451	470
EBITDA pre	71	78
Margin	15.7%	16.6%

Net of exceptionals and amortization of intangible assets as well as attributable tax effects
 Balance sheet items at 31.12.2017 include 100% ARLANXEO

After deduction of time deposits and securities available for sale

Q4 2018: Engineering Materials continuously strong on high level, Performance Chemicals still weak





- BU MPP and BU LPT with price and volume increases driven by good demand
- Price and volume decline in BU IPG and BU LEA reflect site closure, lower chrome prices (both LEA) and softer construction market (IPG)
- Consequently, EBITDA pre and margin drop

[€ m]	Q4'17	Q4'18
Sales	339	323
EBITDA pre	48	24
Margin	14.2%	7.4%



- Strong price increase mainly driven by successful raw material price pass-through in BU HPM
- Volume increase in BU HPM, however somewhat inflated by a trade business deal
- Solid EBITDA pre and margin reflect good operational performance

[€ m]	Q4'17	Q4'18
Sales	340	391
EBITDA pre	35	43
Margin	10.3%	11.0%

11

Ongoing political risks lead to increased uncertainty about economic development



Relevant economic trends 2019

- General economic development is uncertain
- Moderate softening in auto premium segment in China assumed
- China growth expected on lower level

LANXESS FY 2019 EBITDA pre expected around previous year's level (including IFRS 16 effect)*

LANXESS Q1 2019

 Stable YoY development (including IFRS 16 effect) despite weakening of some markets



Self-help measures in place to achieve goals and become more resilient



Self-help measures

- Debottlenecking and brownfield growth capex (ROCE of ~20%)
- Implementation of remaining €30 m synergies from Chemtura until 2020
- Saltigo improvement
- Take Organometallics' margin to industry level (~15%)
- Further portfolio alignment

On track to read	ch financial goals for 2021
EBITDA pre margin (group, Ø through the cycle)	14-18%
Cash con- version*	>60%
EBITDA pre margin volatility	2-3%pts

* Cash conversion: (EBITDA pre – capex) / EBITDA pre

Agenda




- 1 Executive summary FY 2018 and Q4 2018
- 2 Business and financial details Q4 2018
- 3 Back-up

Q4 2018: Positive price and volume growth offset by higher operating costs



Q4 yoy sales variances	Price	Volume	FX	Portfolio	Total
Advanced Intermediates	+8%	+11%	1%	0%	+20%
Specialty Additives	+3%	-2%	+0%	+4%	+4%
Performance Chemicals	-1%	-4%	+1%	-1%	-5%
Engineering Materials	+5%	+9%	+1%	0%	+15%
LANXESS	+4%	+3%	+1%	+1%	+8%

- Sales growth driven by successful raw material price pass-through (esp. BUs AII, ADD and HPM) and increased volumes in segment Advanced Interm. and BU HPM
- Effect from acquisition of Solvay's phosphorus additives mitigated by divestment of chlorine dioxide business



- Flat EBITDA pre: higher volumes offset by higher operating costs (e.g. energy, freight)
- "Other" cost items mitigated by positive FX effects

Q4 2018: Good operational performance and ARLANXEO divestment drive net income



[€ m]	Q4	2017	Q4	2018	yoy in %
Sales	1,635	(100%)	1,766	(100%)	8%
Cost of sales	-1,240	(-76%)	-1,381	(-78%)	-11%
Selling	-207	(-13%)	-213	(-12%)	-3%
G&A	-104	(-6%)	-89	(-5%)	14%
R&D	-22	(-1%)	-30	(-2%)	-36%
EBIT	40	(2%)	45	(3%)	13%
Profit from continuing operations	-48	(-3%)	15	(1%)	>100%
Profit from discontinued operations	-1	(0%)	111	(6%)	>100%
Minorities	0	(0%)	27	(2%)	>100%
Net Income	-49	(-3%)	99	(6%)	>100%
EPS pre* (continuing)	0.43		0.61		42%
EBITDA	147	(9%)	166	(9%)	13%
thereof exceptionals	-32	(-2%)	-13	(-1%)	-59%
EBITDA pre exceptionals	179	(10.9%)	179	(10.1%)	0%

- Sales increase due to higher prices and volumes
- Increase in selling expenses driven by higher freight costs
- Improved G&A costs mainly reflect synergies and variable compensation
- Higher R&D costs due to product registrations and new strategic projects
- Net income boosted by book gain from ARLANXEO divestment (€90 m); PY impacted by one-time effect from U.S. tax reform

Solid result in challenging environment

Q4 2018: Sales and double-digit EBITDA growth in three segments, Performance Chemicals weak







^{*} Total group sales including reconciliation

Q4 2018: Sales increase in most regions – slightly softer demand in Asia







Cash flow Q4 2018: Timing of some items impacts operating cash flow



[€ m]	Q4 2017	Q4 2018
Profit before tax	10	14
Depreciation & amortization	107	121
Financial (gain) losses	19	23
Income taxes paid	-18	-63
Changes in other assets and liabilities	32	-27
Operating cash flow before changes in WC	151	68
Operating cash flow before changes in WC Changes in working capital	151 124	68 117
Changes in working capital	124	117
Changes in working capital Operating cash flow (continuing operations)	124 275	117 185

- Incomparable timing of tax payments
- Changes in other assets and liabilities driven by lower provisions for variable compensation and utilization of provisions, e.g. restructuring
- Changes in working capital comparable to previous year's level
- Investing cash flow significantly improved due to proceeds from ARLANXEO divestment, reduced by pension funding and investment of remaining amount
- Capex increase driven by debottlenecking investment program

19

Balance Sheet: Solid!



[€ m]	31.12.20171	30.09.2018	31.12.2018
Total assets	10,411	10,545 ¹	8,687
Equity (incl. non-controlling interest)	3,413	3,626 ¹	2,773
Equity ratio	33%	34%1	32%
Net financial debt (incl. Treasury Financial Assets)	2,252	2,514	1,381
Near cash, cash & cash equivalents	588	181	797
Pension provisions	1,490	1,247	1,083
ROCE ²	9.3%	-	11.4%
Net working capital	1,948	1,535	1,455
DSI (in days) ³	65	68	69
DSO (in days) ⁴	51	46	46

- Reduced total assets due to deconsolidation of ARLANXEO
- Substantially reduced net financial debt resulting from ARLANXEO divestment
- Cash proceeds partly included in treasury financial assets
- Significantly lower pension provisions due to €200 m funding
- Improved ROCE reflects higher return of New LANXESS
- Seasonal improvement in net working capital

Reduced total assets and liabilities due to deconsolidation of ARLANXEO



[€ m]	Dec 2017	Sep 2018	Dec 2018		Dec 2017	Sep 2018	Dec 2018
Non-current assets	6.454	4.651	4.786	Stockholders' equity	3.413	3.626	2.773
Intangible assets	1.784	1.737	1.764	attrib. to non-contr. interests	1.126	1.120	-7
Property, plant & equipment	4.059	2.448	2.577	Non-current liabilities	4.540	4.601	4.395
Equity investments	0	0	0	Pension & post empl. provis.	1.490	1.247	1.083
Other investments	9	1	2	Other provisions	460	367	337
Other financial assets	20	25	25	Other financial liabilities	2.242	2.684	2.686
Tax receivables	20	14	14	Tax liabilities	134	102	117
Other non-current assets	562	426	404	Other liabilities	101	87	83
Current assets	3.957	5.894	3.901	Deferred taxes	113	114	89
Inventories	1.680	1.348	1.347	Current liabilities	2.458	2.318	1.519
Trade account receivables	1.316	920	903	Other provisions	525	421	465
Other current financial assets	7	50	598	Other financial liabilities	633	42	59
Other current assets	366	237	256	Trade accounts payable	1.048	733	795
Near cash assets	50	50	0	Tax liabilities	61	51	44
Cash and cash equivalents	538	131	797	Other liabilities	191	168	156
Assets from disc. operations	0	3.158	0	Liabilities from disc. operations	0	903	0
Total assets	10.411	10.545	8.687	Total equity & liabilities	10.411	10.545	8.687
Balance sheet as of 31st Dec 2018 no longer includes ARLANXEO							

21

Agenda



- 1 Executive summary FY 2018 and Q4 2018
- 2 Business and financial details Q4 2018
- 3 Back-up

Housekeeping items



LANXESS financial expectations

Capex 2019: ~€500 m
 Operational D&A 2019: ~€450 m

• Reconciliation 2019: ~€150 m - €160 m including remnant costs

• Tax rate: lower end of 30-35%

• Exceptionals 2019: €30 m - €60 m based on current initiatives

• FX sensitivity: one cent change of USD/EUR resulting in

~€7 m EBITDA pre impact before hedging




IFRS 16 effects:


- Reclassification of ~€35 m from operating result to depreciation and interest expense (low single-digit millions) leading to EBITDA pre improvement
- Rise in fair value of leasing liabilities by ~€130 m burdening net debt

23

FY 2018: Strong sales growth in all regions except Latin America








^{*} All figures are indicative only
** Currency and portfolio adjusted

FY 2018: Most segments with strong sales and EBITDA pre growth






^{*} Total sales including reconciliation

FY 2018: Strong operating development and portfolio effect drive financials



FY18 yoy sales variances	Price	Volume	FX	Portfolio	Total
Advanced Intermediates	+8%	+4%	-2%	+2%	+12%
Specialty Additives	+3%	-1%	-2%	+23%	+23%
Performance Chemicals	+0%	-2%	-3%	-2%	-6%
Engineering Materials	+6%	+5%	-1%	+6%	+15%
LANXESS	+4%	+1%	-2%	+7%	+10%

- Strong sales growth due to successful raw material price passthrough (esp. BUs All, ADD and HPM) and portfolio effect
- Strong volume growth in BUs All and HPM mitigated by decline in BU LEA and plant closures in BU ADD
- FX headwind especially in first half of 2018



- EBITDA pre increase driven by successful price pass-through and portfolio
- "Other" includes inflated other operating costs and negative FX impact, over compensated by positive portfolio effect

FY 2018: Financials driven by good operating performance and acquisitions



[€ m]	FY 2017		FY 2018		yoy in %
Sales	6,530	(100%)	7,197	(100%)	10%
Cost of sales	-4,796	(-73%)	-5,363	(-75%)	-12%
Selling	-761	(-12%)	-826	(-11%)	-9%
G&A	-326	(-5%)	-307	(-4%)	6%
R&D	-103	(-2%)	-118	(-2%)	-15%
EBIT	299	(5%)	504	(7%)	69%
Profit from continuing operations	60	(1%)	272	(4%)	>100%
Profit from discontinued operations	64	(1%)	251	(3%)	>100%
Non-controlling interests	37	(1%)	92	(1%)	>100%
Net Income	87	(1%)	431	(6%)	>100%
EPS pre* (continuing)	3.84		4.45		16%
EBITDA	709	(11%)	935	(13%)	32%
thereof exceptionals	-216	(-3%)	-81	(-1%)	-62%
EBITDA pre exceptionals	925	(14.2%)	1,016	(14.1%)	10%

- Sales driven by price passthrough and acquired businesses (Chemtura, Solvay), FX burdens
- Disproportionate rise in cost of sales due to increased operational costs (e.g. energy, environmental)
- Improved G&A costs reflect reclassification effect from discontinued operations
- Significant EBIT boost due to good performance and lower exceptionals
- Book gain from rubber divestment included in profit from disc. ops.

LANXESS achieves very good results in new setup

FY 2018: Cash flow reflects good operational performance mitigated by higher working capital



[€ m]	FY 2017	FY 2018
Profit before tax	219	390
Depreciation & amortization	410	431
Financial (gain) losses	35	63
Cash tax payments/refunds	-139	-156
Changes in other assets and liabilities	108	-90
Operating cash flow before changes in WC	634	637
Changes in working capital	-66	-165
Operating cash flow (continuing operations)	568	472
Investing cash flow (continuing operations)	-22	65
Thereof capex	-397	-497
Thereof M&A / ARLANXEO divestment	-1,794	1,238
Thereof CTA* funding	0	-200
Financing cash flow (continuing operations)	-545	-160

- Changes in other assets and liabilities driven by higher cash outs for variable compensation and restructuring
- Changes in working capital in line with increase of sales, working capital in % of sales stable
- Investing cash flow contains:
 - Capex increases due to growth capex in debottlenecking
 - €1.4 bn proceeds from ARLANXEO divestment
 - €200 m pension funding (CTA)
 - Deposit of ~€500 m in fin. assets
- Financing cash flow includes
 Chemtura bond redemption in 2017

^{*} Net of exceptionals and amortization of intangible assets as well as attributable tax effects and non-recurring effects of the U.S. tax reform (2017)

Capital allocation priorities after ARL exit: Focus on deleveraging and building a superior growth platform

€200 m 🔻



Capital allocation after receipt of cash

M&A following our communicated financial matrix

Attractive growth

 Investments into new and already announced brownfield & debottlenecking projects (until ~2021)

€400 – €X m

Deleveraging

- Funding of German pension liabilities
- New funding ratio improved to ~57%*

Share buy-back

 Share buy-back to be executed between January and year end 2019

up to €200 m

Use of proceeds in line with investment grade commitment

of ~ €400 m - €500 m

29 * based on pensions at 31st of December 2018

LANXESS delivers on organic growth – upcoming capacity expansions




Organio	investment program well on track	Capex
BU AII:	Capacity increase for DCB* initiated, Leverkusen (Germany finalized beginning 2019), not discl.
	Expansion of hexandiol production, Krefeld-Uerdingen	not discl.
BU RCH:	Capacity expansion for Macrolex brand dyes, in Q2 2019	~€5 m
BU LPT:	lon exchange resigns production, Leverkusen (Germany), completion in H1 2019	single-digit €m
BU IPG:	Planned capacity increase for iron oxides pigments, Germany and Brazil, through 2019	not discl.
BU HPM:	New compounding facility in Changzhou (China), available Q2 2019, further expansion of engineering plastics capacity	~€20 m
	New compounding facility, Krefeld-Uerdingen (Germany), available in the second half of 2019	nid double-digit €m
BU URE:	Additional prepolymers capacity, Porto Feliz (Brazil), available mid 2019	<€10 m



Chemtura synergies realized ahead of plan





Key Messages


- Synergies confirmed
 - €100 m of "hard" costs
 - Earlier realization
 - Topline synergies not included
- OTCs and cash-outs confirmed
- Capex confirmed, mainly related to Manufacturing Excellence

Maturity profile actively managed and well balanced



Long-term financing secured


- Diversified financing sources
 - Bonds & private placements
 - Syndicated credit facility
- Average interest rate of financial liabilities 2%
- Closing of ARLANXEO transaction per end of December 2018. Cash proceeds of around €1.4 bn
- Next bond maturity in 2021
- All group financing executed without financial covenants




^{*} Does not include ~€65 m PPA charges from inventory step-up in opening balance sheet. Transaction related charges were recognized in opening balance sheet

Substantially reduced dependency on volatile raw materials





* average 2013 = 100%



Significantly reduced exceptional items (on EBIT) in 2018



[€ m]	Q4 :	2017	Q4 2018		FY 2017		FY 2018	
	Excep.	Thereof D&A	Excep.	Thereof D&A	Excep.	Thereof D&A	Excep.	Thereof D&A
Advanced Intermediates	4	0	0	0	7	0	0	0
Specialty Additives	8	1	-6	1	111	36	3	0
Performance Chemicals	-2	0	12	10	68	6	13	10
Engineering Materials	0	0	0	-1	13	1	1	0
Reconciliation	22	-1	17	0	60	0	74	0
Total	32	0	23	10	259	43	91	10

Upcoming events 2019



Proactive capital market communication		
FY 2018 results	March 14	
■ Goldman Sachs 8 th Annual European Chemicals Conference	March 15	London
MainFirst Corporate Conference	March 28	Copenhagen
 Q1 2019 results 	May 14	
Annual Stockholders' Meeting	May 23	Cologne
mBank Chemicals Day	June 3/4	Warsaw
dbAccess Berlin Conference	June 5/6	Berlin
 Exane BNP Paribas 21st CEO Conference 	June 11/12	Paris
J.P. Morgan Cazenove European Materials Conference	June 12	London
Morgan Stanley Cannon Ball Run	June 25	Cologne
 Q2 2019 results 	August 2	
 Q3 2019 results 	November 13	
Meeting the Management	November 15	Cologne

Contact details Investor Relations





Oliver Stratmann Head of Treasury & Investor Relations

Tel.: +49-221 8885 9611

Fax.: +49-221 8885 5400 Mobile: +49-175 30 49611 Email: Oliver.Stratmann@lanxess.com



André Simon Head of Investor Relations

Tel.: +49-221 8885 3494 Mobile: +49-175 30 23494 Email: Andre.Simon@lanxess.com



Laura Stankowski

Assistant to André Simon Tel.: +49-221 8885 3262 Fax.: +49-221 8885 4944 Email: Laura.Stankowski@lanxess.com



Katharina Forster Institutional Investors / Analysts / AGM

Tel.: +49-221 8885 1035 Mobile: +49-151 7461 2789 Email: Katharina.Forster@lanxess.com



Eva Frerker

Tel.: +49-221 8885 5249



Janna Günther Private Investors / AGM

Tel.: +49-221 8885 1989 Mobile: +49 151 7461 2615 Email: Janna.Guenther@lanxess.com



Jens Ussler Institutional Investors / Analysts

Tel.: +49-221 8885 7344 Mobile: +49 151 74612913 Email: Jens.Ussler@lanxess.com



Abbreviations



Advanced Intermediates

• All Advanced Industrial Intermediates

• SGO Saltigo

Performance Chemicals

• IPG Inorganic Pigments

• LEA Leather

• MPP Material Protection Products

• LPT Liquid Purification Technologies

Specialty Additives

ADD Additives

• RCH Rhein Chemie

Engineering Materials

• **HPM** High Performance Materials

• URE Urethane Systems